회사소개

  • 회사소개
  • 비전
  • 연혁
  • 기술자문그룹
  • 주요경영진
  • 오시는길
  • 인재채용

History

Home / About Kainos Medicine / History

2020.07 : KM023 was filed for NDA in CFDA / 2020.06 : Listed in KOSDAQ
Passed Korea Stock Exchange Technology Evaluation with two A grades.
2018. 01 Set up FAScinate Therapeutics Inc. of incorporation in USA 2018. 01 co-representative Yoo Sung-Eun 2018. 05 signing Joint Research for Parkinsons drug development with Parkinsons Institute and Clinical Center
2017. 01 Set-up Kainos Drug Research Center located in KRICT 2017. 10 Signing Joint Research for Parkinsons drug development with University of California San Diego 2017. 10 Completing phase 1 for Parkinsons drug, KM-819
2013.01 signing 'Global drug research collaboration agreement' with Korea University 2013.02 filing PCT patent application for diabetes & obesity drug 2013.08 filing PCT patent application for targeted cancer drug
2013.01 signing 'Global drug research collaboration agreement' with Korea University 2013.02 filing PCT patent application for diabetes & obesity drug 2013.08 filing PCT patent application for targeted cancer drug
2013.01 signing 'Global drug research collaboration agreement' with Korea University 2013.02 filing PCT patent application for diabetes & obesity drug 2013.08 filing PCT patent application for targeted cancer drug
2013.01 signing 'Global drug research collaboration agreement' with Korea University 2013.02 filing PCT patent application for diabetes & obesity drug 2013.08 filing PCT patent application for targeted cancer drug
2012.05 holding 'Kainos Symposium for successful drug development' 2012.08 filing US provisional patent application for epigenetics cancer drug 2012.11 signing 'License agreement for HIV drug' with KRICT 2012.12 signing 'Licensing and collaboration agreement for global drug development' with Hanmi Pharmaceutical Co. Research collaboration with Asan Medical Center for molecular targeted cancer drug
2011.02 set-up 'Kainos Drug Research Center' located in Asan Medical Center 2011.03 IND approval from KFDA for phase 1 trial of HIV drug, KM023 2011.06 starting phase 1 study for KM023 in Seoul National University Hospital Clinical Trial Center
2010.03 completing phase 2a study for Xerostomia drug, KM552 2010.04 signing 'collaboration agreement for HIV drug, KM023' with KRICT 2010.06 funding government research grant for diabetes & obesity drug discovery project 2010.09 selected as INNO-BIZ Company 2010.12 fund raising from 5 venture capitals
2008.05 selected for government grant from evaluation program for patent technology 2008.07 signing 'In-licensing agreement for Xerostomia drug, KM552' with Parion Sciences 2008.08 set-up 'Kainos Research Center' in North Carolina, US 2008.10 funding government research grant for KM552 from Bio Star Project.
2007.06 established Kainos Medicine, Inc. 2007.09 funding government grant of Licensing Management Support Program 2007.12 certified as a venture company from government